Literature DB >> 1279207

Mutagenesis of the Glu-89 residue in human immunodeficiency virus type 1 (HIV-1) and HIV-2 reverse transcriptases: effects on nucleoside analog resistance.

Q Song1, G Yang, S P Goff, V R Prasad.   

Abstract

A Glu-89-->Gly alteration in the human immunodeficiency virus type 1 reverse transcriptase (RT) was previously shown to result in resistance to several dideoxynucleoside analogs and to phosphonoformic acid (PFA; foscarnet). This residue was altered to Ala, Val, Ser, Thr, Gln, Asp, Asn, or Lys, and the ddGTP and PFA sensitivities of the mutant RTs were measured. Replacements with Ala, Gly, Val, and Thr led to resistance to inhibition by ddGTP, while mutants with amino acid Ser, Gln, Asn, Asp, or Lys displayed only moderate or no resistance. A similar result was obtained with inhibition by PFA, except that the Asp-89 mutant also displayed resistance. Furthermore, the introduction of Glu-89-->Gly alteration into the RT of human immunodeficiency virus type 2 likewise rendered it resistant to both ddGTP and PFA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1279207      PMCID: PMC240471          DOI: 10.1128/JVI.66.12.7568-7571.1992

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  15 in total

1.  Expression of reverse transcriptase activity of human T-lymphotropic virus type III (HTLV-III/LAV) in Escherichia coli.

Authors:  N Tanese; J Sodroski; W A Haseltine; S P Goff
Journal:  J Virol       Date:  1986-09       Impact factor: 5.103

2.  In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.

Authors:  Q Gao; Z X Gu; M A Parniak; X G Li; M A Wainberg
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

3.  A novel in situ colony screening method to detect human immunodeficiency virus reverse transcriptase activity expressed in bacteria. Isolation of pseudorevertants of reverse transcriptase mutants.

Authors:  V R Prasad; S P Goff
Journal:  J Biol Chem       Date:  1989-10-05       Impact factor: 5.157

4.  Structural requirements for bacterial expression of stable, enzymatically active fusion proteins containing the human immunodeficiency virus reverse transcriptase.

Authors:  N Tanese; V R Prasad; S P Goff
Journal:  DNA       Date:  1988 Jul-Aug

5.  Rapid and efficient site-specific mutagenesis without phenotypic selection.

Authors:  T A Kunkel
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

6.  Infectious potential of human immunodeficiency virus type 1 reverse transcriptase mutants with altered inhibitor sensitivity.

Authors:  B A Larder; S D Kemp; D J Purifoy
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

7.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

Authors:  B A Larder; S D Kemp
Journal:  Science       Date:  1989-12-01       Impact factor: 47.728

8.  Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.

Authors:  M H St Clair; J L Martin; G Tudor-Williams; M C Bach; C L Vavro; D M King; P Kellam; S D Kemp; B A Larder
Journal:  Science       Date:  1991-09-27       Impact factor: 47.728

9.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor.

Authors:  L A Kohlstaedt; J Wang; J M Friedman; P A Rice; T A Steitz
Journal:  Science       Date:  1992-06-26       Impact factor: 47.728

10.  Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine.

Authors:  J E Fitzgibbon; R M Howell; C A Haberzettl; S J Sperber; D J Gocke; D T Dubin
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

View more
  11 in total

1.  The frameshift signal of HIV-1 involves a potential intramolecular triplex RNA structure.

Authors:  Jonathan D Dinman; Sara Richter; Ewan P Plant; Ronald C Taylor; Amy B Hammell; Tariq M Rana
Journal:  Proc Natl Acad Sci U S A       Date:  2002-04-16       Impact factor: 11.205

2.  The nucleoside analog-resistant E89G mutant of human immunodeficiency virus type 1 reverse transcriptase displays a broader cross-resistance that extends to nonnucleoside inhibitors.

Authors:  Y Kew; H Salomon; L R Olsen; M A Wainberg; V R Prasad
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

3.  The glutamine side chain at position 91 on the β5a-β5b loop of human immunodeficiency virus type 1 reverse transcriptase is required for stabilizing the dNTP binding pocket.

Authors:  Nootan Pandey; Chaturbhuj A Mishra; Dinesh Manvar; Alok K Upadhyay; Tanaji T Talele; Thomas W Comollo; Neerja Kaushik-Basu; Virendra N Pandey
Journal:  Biochemistry       Date:  2011-08-23       Impact factor: 3.162

4.  Increased polymerase fidelity of E89G, a nucleoside analog-resistant variant of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  W C Drosopoulos; V R Prasad
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

5.  Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA.

Authors:  A Jacobo-Molina; J Ding; R G Nanni; A D Clark; X Lu; C Tantillo; R L Williams; G Kamer; A L Ferris; P Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

6.  The Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.

Authors:  Antonio J Acosta-Hoyos; Walter A Scott
Journal:  Viruses       Date:  2010-01-28       Impact factor: 5.048

7.  Relationship between 3'-azido-3'-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Peter R Meyer; Suzanne E Matsuura; Dianna Zonarich; Rahul R Chopra; Eric Pendarvis; Holly Z Bazmi; John W Mellors; Walter A Scott
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

8.  Specificity of interaction of INI1/hSNF5 with retroviral integrases and its functional significance.

Authors:  Eric Yung; Masha Sorin; Emilie-Jeanne Wang; Seena Perumal; David Ott; Ganjam V Kalpana
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

9.  Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not.

Authors:  P L Boyer; C Tantillo; A Jacobo-Molina; R G Nanni; J Ding; E Arnold; S H Hughes
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

Review 10.  Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.

Authors:  A J Wagstaff; H M Bryson
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.